Data from a small, early-stage safety trial testing Moderna Inc's experimental COVID-19 vaccine does not provide critical data to assess its effectiveness, Stat News reported on Tuesday, citing experts.
Moderna said on Monday the vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers.
The news based on data from eight people who took part in a 45-subject safety trial sent the company’s shares up nearly 20% on Monday and also pushed the markets higher.The company’s shares closed down 10.4% at $71.67.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna Says Initial Covid-19 Vaccine Results Are PositiveModerna said human subjects in a Phase 1 trial of a candidate Covid-19 vaccine produced immune responses that were a positive sign of the vaccine’s potential to prevent infection with the new coronavirus
Read more »
Stéphane Bancel, CEO of Moderna, the biotech making a COVID-19 vaccine - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Read more »
Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccineHeavy hearts soared Monday with news that Moderna's Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects.
Read more »
Amanda Kloots Celebrates a 'Small Win' Amid Husband's COVID-19 FightNick Cordero is continuing to fight the coronavirus in the hospital.
Read more »
Make No Mistake: Leaders Are Using COVID-19 to Block Abortion Access'I want all the people trying to block access to reproductive care to know there is a generation of young people prepared to stand up and fight for their rights.' sidneyflanigan of neverrarelyfilm on why abortion is essential healthcare.
Read more »